GHK-CU · DECODED
GHK-Cu
Decoded · Topical Evidence · Injectable Unproven
BY THE NUMBERS
HOW IT WORKS
A copper-binding tripeptide. Proposed to upregulate TGF-β signaling, stimulate collagen and fibronectin synthesis, and activate VEGF-driven angiogenesis. The topical mechanism has support from multiple randomized controlled trials. Injectable and systemic mechanisms are extrapolated from topical data and animal studies. No human interventional trials exist for systemic GHK-Cu administration.
WHERE IT CAME FROM
GHK-Cu, or glycyl-L-histidyl-L-lysine copper, is a naturally occurring copper-binding tripeptide (three amino acids) produced in the body and found in blood plasma, saliva, and urine. Loren Pickart first described it in 1973 while researching factors that could restore liver tissue function, and subsequent work showed that GHK has high affinity for copper ions and that the copper-bound form (GHK-Cu) is biologically active in ways the copper-free tripeptide is not. Proposed mechanisms include upregulation of collagen synthesis, activation of antioxidant enzymes, and modulation of wound-healing genes. The compound became a significant ingredient in cosmetic and dermatology research in the 1990s and 2000s.
The two versions in current use, topical and injectable, have completely different evidence profiles and should not be treated as equivalent. Topical GHK-Cu has been studied in randomized controlled trials for skin aging endpoints. Injectable or systemic GHK-Cu has no completed human interventional trials. The injectable form circulating in the grey market is an extrapolation from the topical evidence base plus preclinical data. That extrapolation is not supported by controlled human data.
THE STUDIES
WHAT THE STUDIES SHOW
TOPICAL (CLINICAL DATA)
- ▸Significant wrinkle reduction vs. control across multiple RCTs
- ▸Skin firmness improvement across trials
- ▸Tolerability well-established in topical use
- ▸High heterogeneity across trials: results vary by formulation and population
PRECLINICAL (INJECTABLE)
- ▸Collagen synthesis upregulation in cell models
- ▸Wound healing acceleration in animal models
- ▸Antioxidant enzyme activation in preclinical settings
- ▸Gene expression modulation: hundreds of genes influenced
UNKNOWN (INJECTABLE IN HUMANS)
- ▸Effective dose range systemically
- ▸Whether topical effects translate to injectable use
- ▸Systemic safety profile: zero controlled human data
- ▸Bioavailability and distribution after injection
SIDE EFFECTS
TOPICAL (KNOWN)
- ▸Contact dermatitis in sensitive individuals
- ▸Mild skin irritation at high concentrations
- ▸Well-tolerated at standard cosmetic concentrations
- ▸Copper staining of skin/fabric at high doses
INJECTABLE (UNKNOWN / EXTRAPOLATED)
- ▸No controlled human safety data for injectable form
- ▸Copper toxicity is a theoretical concern at high systemic doses (copper homeostasis is tightly regulated)
- ▸Grey market supply: purity, sterility, and copper content unverified
- ▸Regulatory gray zone: April 2026 Category 2 removal does not authorize compounding
REGULATORY STATUS
GHK-Cu was on the FDA's Category 2 list, prohibiting it from 503A compounding. On April 15, 2026, the FDA removed GHK-Cu from that explicit prohibition. Of the 12 compounds removed, GHK-Cu is often noted as having the strongest evidence base, though that assessment applies to the topical form. The PCAC is scheduled to review GHK-Cu injectable at a second meeting before February 2027 (exact date pending). Topical GHK-Cu in cosmetic formulations is not subject to pharmaceutical compounding regulations and can be used in skin care products. Injectable GHK-Cu has no approved pathway. The April 2026 Category 2 removal does not authorize compounding pharmacies to produce injectable GHK-Cu.
PROS & CONS
PROS
- +Topical form has the best evidence base of any compound in this regulatory gray zone
- +Endogenous compound with naturally occurring copper-binding function
- +Mechanistically grounded: collagen synthesis and wound healing pathways are well-characterized
- +Topical safety profile is well-established
- +Of the April 2026 Category 2 removal group, GHK-Cu has the most developed topical evidence base
CONS
- −Injectable form has zero completed human interventional trials
- −High heterogeneity in topical meta-analysis means effect size is uncertain
- −40% of topical studies are industry-funded
- −Grey market injectable supply: no quality control
- −Copper toxicity risk at supraphysiologic systemic doses is an open safety question
- −Topical evidence is not injectable evidence. The forms should not be equated.
DAILY PEPTIDE VERDICT
RANKING
GHK-Cu has a genuine evidence base, but it is entirely in the topical domain. Seven randomized trials and 456 subjects is a real foundation for wrinkle reduction and skin aging claims. That data does not extend to injectable use, which has no completed human clinical trials. The injectable form is sold and used in the grey market on the assumption that the systemic administration of a topically-active compound will produce systemic effects, a logical extrapolation that has not been tested in humans. The PCAC review before February 2027 is the next real inflection point for GHK-Cu's regulatory future. If it moves onto the 503A approved list, licensed compounding becomes possible and the quality question improves. Until then, topical use has a real evidence base; injectable use is an educated guess.
DISCLAIMER · EDUCATIONAL USE ONLY
This document is for educational and informational purposes only. GHK-Cu does not hold general FDA approval for human use. Information here synthesizes publicly available research data and does not constitute medical advice.